Spots Global Cancer Trial Database for Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

Official Title: Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)

Study ID: NCT03575598

Conditions

Squamous Cell Carcinoma, Head And Neck

Squamous Cell Carcinoma Mouth

Squamous Cell Carcinoma of the Oral Cavity

Interventions

Sitravatinib

Nivolumab

Study Description

Brief Summary: This is a window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative drugs, Sitravatinib and Nivolumab.

Detailed Description: This is a single center, open-label, non-randomized, pre-operative window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative Sitravatinib and Nivolumab. A total of 12 patients who are evaluable for correlative studies, are planned for enrollment. This study will involve treatment with Sitravatinib and Nivolumab, tests and procedures done for safety and the collection of blood samples for biomarker research. Tissue samples (fresh biopsy or archival tissue) will also be collected for biomarker research and evaluation.